Cargando…

Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis

OBJECTIVE: Suitable biomarkers are essential for the design of therapeutic strategies in personalized medicine. Vasoactive intestinal peptide (VIP) has demonstrated immunomodulatory properties in autoimmune murine and ex vivo human models. Our aim was to study serum levels of VIP during the follow-u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez, Carmen, Ortiz, Ana M., Juarranz, Yasmina, Lamana, Amalia, Seoane, Iria V., Leceta, Javier, García-Vicuña, Rosario, Gomariz, Rosa P., González-Álvaro, Isidoro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883710/ https://www.ncbi.nlm.nih.gov/pubmed/24409325 http://dx.doi.org/10.1371/journal.pone.0085248

Ejemplares similares

Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis
por: Seoane, Iria V., et al.
Publicado: (2018)

Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity
por: Seoane, Iria V., et al.
Publicado: (2015)

Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity
por: Seoane, Iria V., et al.
Publicado: (2016)

Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis
por: Juarranz, Yasmina, et al.
Publicado: (2005)

The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis
por: Villanueva-Romero, Raúl, et al.
Publicado: (2018)

Human CD4(+)CD45RA(+) T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide
por: Villanueva-Romero, Raúl, et al.
Publicado: (2022)

Vasoactive intestinal peptide axis is dysfunctional in patients with Graves’ disease
por: Carrión, M., et al.
Publicado: (2020)

An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance
por: Gomariz, Rosa P., et al.
Publicado: (2019)

Mechanism of Immunoregulatory Properties of Vasoactive Intestinal Peptide in the K/BxN Mice Model of Autoimmune Arthritis
por: Leceta, Javier, et al.
Publicado: (2021)

The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP
por: Jimeno, Rebeca, et al.
Publicado: (2014)

The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis
por: Castro-Vazquez, David, et al.
Publicado: (2021)

A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases
por: Martínez, Carmen, et al.
Publicado: (2019)

Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity
por: Lamana, Amalia, et al.
Publicado: (2020)

Comparative Study of Senescent Th Biomarkers in Healthy Donors and Early Arthritis Patients. Analysis of VPAC Receptors and Their Influence
por: Villanueva-Romero, Raúl, et al.
Publicado: (2020)

VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures
por: Lamana, Amalia, et al.
Publicado: (2022)

The Minor Allele of rs7574865 in the STAT4 Gene Is Associated with Increased mRNA and Protein Expression
por: Lamana, Amalia, et al.
Publicado: (2015)

VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts
por: Pérez‐García, Selene, et al.
Publicado: (2016)

Biomarkers Predicting a Need for Intensive Treatment in Patients with Early Arthritis
por: I, González-Álvaro, et al.
Publicado: (2015)

Role of vasoactive intestinal peptide in osteoarthritis
por: Jiang, Wei, et al.
Publicado: (2016)

Inhibitory Role of Growth Hormone in the Induction and Progression Phases of Collagen-Induced Arthritis
por: Villares, Ricardo, et al.
Publicado: (2018)

Vasoactive intestinal peptide secreting tumour: An overview
por: Una Cidon, Esther
Publicado: (2022)

Electroacupuncture Inhibits Inflammation Reaction by Upregulating Vasoactive Intestinal Peptide in Rats with Adjuvant-Induced Arthritis
por: He, Tian-Feng, et al.
Publicado: (2011)

Profile of Matrix-Remodeling Proteinases in Osteoarthritis: Impact of Fibronectin
por: Pérez-García, Selene, et al.
Publicado: (2019)

Vasoactive intestinal peptide producing pheochromocytoma and intracardiac thrombosis
por: Hermel, Melody, et al.
Publicado: (2021)

Select cognitive deficits in Vasoactive Intestinal Peptide deficient mice
por: Chaudhury, Dipesh, et al.
Publicado: (2008)

Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide
Publicado: (1987)

The effects of vasoactive intestinal peptide on RANKL-induced osteoclast formation
por: Qu, Hongyi, et al.
Publicado: (2021)

Chronic Diarrhea Caused by Vasoactive Intestinal Peptide-Secreting Tumor
por: Belei, Oana, et al.
Publicado: (2023)

Anti-citrullinated protein antibodies and bone loss in patients with early arthritis: comment on the article “Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis” by Bugatti et al.
por: Castañeda, Santos, et al.
Publicado: (2017)

Validation of galectin-1 as potential diagnostic biomarker of early rheumatoid arthritis
por: Triguero-Martínez, Ana, et al.
Publicado: (2020)

Vasoactive Intestinal Peptide and Its Receptors in Human Ovarian Cortical Follicles
por: Gabbay-Benziv, Rinat, et al.
Publicado: (2012)

Therapeutic effect of vasoactive intestinal peptide on form-deprived amblyopic kittens
por: Li, Bo, et al.
Publicado: (2019)

Vasoactive intestinal peptide regulates ileal goblet cell production in mice
por: Schwerdtfeger, Luke A., et al.
Publicado: (2020)

Hypercalcemia in a Patient Diagnosed with a Vasoactive Intestinal Peptide Tumor
por: Ataallah, Basma, et al.
Publicado: (2020)

Vasoactive intestinal peptide in canine portosystemic shunt in the absence of portal hypertension
por: Isaka, Mitsuhiro, et al.
Publicado: (2021)

Pressure-Dependent Elevation of Vasoactive Intestinal Peptide Level in Chicken Choroid
por: Privalov, Evgeny, et al.
Publicado: (2023)

Genetic LGALS1 Variants Are Associated with Heterogeneity in Galectin-1 Serum Levels in Patients with Early Arthritis
por: Triguero-Martínez, Ana, et al.
Publicado: (2022)

Clostridium difficile suppresses colonic vasoactive intestinal peptide associated with altered motility
por: Nassif, A., et al.
Publicado: (1995)

Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review
por: Wu, Dongmei, et al.
Publicado: (2011)

Role of Vasoactive Intestinal Peptide in Promoting the Pathogenesis of Eosinophilic Esophagitis (EoE)
por: Verma, Alok K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v29nia470ff4ccb72kh10k6fv1